
CLAIMS

1. A PARP1 inhibitor compound for use in medicine, which compound comprises any of the following structures:



wherein:

the dotted lines indicate that the ring D may comprise single bonds, or a combination of both single and double bonds, and may be aliphatic or aromatic;

each X^4 may be the same or different and is independently selected from C, N, O and S;


R^3 is H;

when Z^1 is N, R^6 is absent; when Z^1 is C, R^6 is selected from H, halogen, C_1 to C_3 alkyl, C_1 to C_3 haloalkyl, C_1 to C_3 alcohol or C_1 to C_3 aminooalkyl;

each R^{11} is independently selected from H, a halogen, a nitrile group, a linear or branched C_1-C_3 alkyl group, a linear or branched C_1-C_3 halogenated alkyl group, an -OH group, a linear or branched C_1-C_3 alcohol group, a halogenated linear or branched C_1-C_3 alcohol group, $-NH_2$, a linear or branched primary secondary or tertiary C_1-C_3 amine group, a halogenated linear or branched primary, secondary or tertiary C_1-C_3 amine group, a linear or branched C_1-C_3 alkoxy group, a linear or branched C_1-C_3 halogenated alkoxy group, and/or a pair of R^{11} groups attached to the same atom forming =O; and/or when a pair of R^{11} groups attached to different atoms together forms a ring with ring D atoms, the pair of R^{11} groups comprises $-CH_2CH_2CH_2-$;

Z^1 is selected from C and N;

group L comprises a group having the following structure:



wherein:

n is a number independently selected from 0, 1, 2, 3, 4, 5 and 6;

m is a number independently selected from 0, 1, 2, 3, 4, 5 and 6;

m + n is a number selected from 2, 3, 4, 5, and 6;

p is a number independently selected from 0, 1, 2, 3, 4, 5 and 6;

q is a number independently selected from 0, 1, 2, 3, 4, 5 and 6;

p + q is a number selected from 2, 3, 4, 5, and 6;

r is a number independently selected from 0, 1, 2, 3, 4, and 5;

s is a number independently selected from 0, 1, 2, 3, 4, and 5;

r + s is a number selected from 1, 2, 3, 4, and 5;

each X^1 may be the same or different and is independently selected from C, N, O and S;

each X^2 may be the same or different and is independently selected from C, N, O and S;

each X^3 may be the same or different and is independently selected from C, N, O and S;

X^5 is independently selected from C and N;

each X^6 may be the same or different and is independently selected from C and N;


each R^{41} R^{42}, R^{43} and R^{44} may be the same or different, and may be present or absent, and is selected from H, deuterium, a halogen, a nitrile group, a


substituted or unsubstituted C_1-C_6 alkyl group, a substituted or unsubstituted linear or branched C_1-C_6 halogenated alkyl group, a cyclopropyl group, an -OH group or a substituted or unsubstituted linear or branched C_1-C_6 alcohol group, a substituted or unsubstituted linear or branched C_1-C_7 amino carbonyl group, an $-NH_2$ group or a substituted or unsubstituted C_1-C_6 amino group and a substituted or unsubstituted C_1-C_6 alkoxy group; wherein, when a pair of R^{41} groups attached to different atoms together forms a ring with ring A atoms, and/or a pair of R^{42} groups attached to different atoms together forms a ring with ring B atoms, each of the pair of R^{41} groups and/or pair of R^{42} groups independently comprises $-CH_2-$ or $-CH_2CH_2-$;


the dotted lines indicate that the ring C may comprise single bonds, or a combination of both single and double bonds, and may be aliphatic or aromatic; and


R^5 is selected from H and a substituted or unsubstituted organic group.


2. A compound for use according to claim 1, wherein ring A of the group L comprises any of the following structures:




















3. A compound for use according to claim 2, wherein ring A of the group L comprises any of the following structures:





4. A compound for use according to any preceding claim, wherein ring C of the group L comprises any of the following structures:






5. A compound for use according to claim 4, wherein ring C of the group L comprises any of the following structures:














6. A compound for use according to any preceding claim, wherein the group R^5 is selected from H, -F, -Cl, -Br, -I, -CN, -$CONR^{51}R^{51}$, -$NR^{51}COR^{52}$, -$SO_2NR^{51}R^{51}$, -$NR^{51}SO_2R^{53}$, -$O\text{-}CR^{52}R^{52}R^{52}$, -$CR^{52}R^{52}NR^{51}R^{51}$ and any of the following structures:






wherein, each of R^{51}, R^{52} and R^{53} may be the same or different and are independently selected from H and a substituted or unsubstituted organic group;




7. A compound for use according to claim 6, wherein the group R^5 is selected from -F, -Cl, -CN, -$CONH_2$, -CONHMe, -CONHEt, -$CONMe_2$, -CONHCOMe, -$CONHCH_2$-CH_2OMe, -CONH-CH_2-CH_2F, -CONH-CH_2-CF_3, -CONH-CH_2-CHF_2, -$OCHF_2$, -NHCOMe, -$NHSO_2Me$, -SO_2NHMe, -$CONHSO_2Me$,         and  .

8. A compound for use according to any preceding claim, wherein X^5 is N.


9. A compound for use according to claim 8, wherein the ring B of the group L comprises any of the following structures:

   .


10. A compound for use according to claim 9, wherein the ring B of the group L comprises any of the following structures:


   .


11. A compound for use according to any preceding claim, wherein the group L comprises a group having the following structure:





12. A compound for use according to any preceding claim, wherein the group L comprises a group selected from the following structures:





















13. A compound for use according to any preceding claim, wherein m is selected from 1 or 2, n is selected from 2 or 3, p is selected from 1, 2 or 3 and q is selected from 1 or 2.


14. A compound for use according to claim 12 or claim 13, wherein the group L comprises a group having any the following structures:



















15. A compound for use according to any preceding claim, wherein the group L comprises a group having any the following structures:































































































































































































































































































































































































16. A compound for use according to any preceding claim, which compound comprises any of the following structures:





preferably wherein at least one X^4 is C.


17. A compound for use according to claim 16, which compound comprises any of the following structures:

























































































wherein R^{14} may be present or absent and if present is selected from H, C_1 to C_3 alkyl or C_1 to C_3 fluoroalkyl.


18. A compound for use according to claim 17, which compound comprises any of the following structures:











































































19. A compound for use according to any preceding claim, wherein each R^{11} is independently selected from H, Cl, F, CHF_2, CF_3, CH_3, OH, CH_3O, and NH_2, and/or a pair of R^{11} groups attached to the same atom forming =O; and independently, when a pair of R^{11} groups attached to different atoms together forms a ring with ring D atoms, the pair of R^{11} groups comprises -$CH_2CH_2CH_2$-.


20. A compound for use according to claim 18, which compound comprises any of the following structures:

































O
NH
Cl
N
L



F
O
NH
N
L



O
NH
L



O
NH
F
N
L



O
N
NH
N
L



O
NH
N
N
L



O
NH
F
N
L



Cl
O
NH
L



O
Cl
NH
L



CF3
O
NH
L



F
O
NH
L



O
NH
L
Cl



O
N
NH
N
N
L



O
NH
N
O
N
L



F3C
O
NH
N
H
N
L



F
O
NH
L



O
NH
L



O
NH
N
L



F3C
O
NH
N
L



F3C
O
NH
N
N
H
N
L



O
N
NH
N
L



O
NH
L
CF3



F3C
O
NH
N
N
L



O
NH
L
F



F3C
O
NH
N
O
N
L



F3C
O
NH
L



O
NH
N
L
CF3



F
O
NH
L
F



O
F
NH
N
L
F



F
O
NH
N
L
F



O
NH
S
N
L



F
O
NH
L
F



F3C
O
NH
N
N
N
L



F3C
O
NH
N
HN
L



O
NH
S
N
L



O
N
NH
L



O
NH
N
L



O
NH
N
N
L



O
N
NH
L



O
NH
N
H
L



O
NH
N
H
N
L



O
NH
N
L



O
NH
L
Cl



F
F
O
NH
N
L



O
H
N
NH
N
H
N
L



O
NH
S
N
L



O
NH
L
Me



F3C
O
NH
N
N
L



OMe
O
NH
L



O
NH
L
F



OH
O
NH
L



NH2
O
NH
N
L



O
O
NH
N
L



O
NH
N
L



O
N
NH
N
L
F3C



O
H
N
NH
N
L
F3C



O
NH
N
N
L



O
H
N
NH
N
L
F3C



O
NH
N
N
L



O
N
NH
N
L



O
NH
O
N
H
L



O
F
NH
N
L



O
NH
O
N
L



O
Cl
NH
N
L



O
N
NH
L
F



O
NH
O
L



O
N
NH
N
N
L



O
NH
HO
L



O
NH
HN
L
O



O
N
NH
L
Cl



O
F
NH
N
N
L



O
F
NH
L
F



O
F
NH
N
L



O
O
NH
L



O
O
NH
N
L



O
NH
N
N
L


O
N
N
NH
L
F3C



O
F
NH
L
F


F
O
NH
L
F



O
NH
L
CF3


O
F3C
NH
N
N
L


21. A compound for use according to any preceding claim, which compound comprises a formula selected from one of the following:




1




5




6




10




15




17




18




23




26




27




28




32




34




37




43




44




46




49




52




55




58




60




61




64




66




67




68




69




70




71




74




76




77




78




79




80




81




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




98




99




100




101




102




103




104




105




106




107




108




109




110




111




112




113




114




115




116




117




118




121




122




123




124




125




128




129




130




131




135




136




137




138




139




140




143




145




146




149




150




154




155




156




157




158




159




161




162




163




167




168




170




172




173




174




175




176




177




178




179




180




181




182




183




184




185




186




187




189




190




191




192




194




195




196




197




198




199




200




202




203




204




205




206




208




209




211




214




215




218




219




220




221




222




223




224




226




227




228




229




230




232




233




234




235




236




237




238




241




244




245




247




248




249




250




251




252




253




254




258




259




260




262




263




265




266




267




268




270




271




272




273




274




275




277




280




281




283




284




288




289




290




291




292




293




294




295




296




301




302




303




304




305




306




307




308




309




311




312




314




315




316




318




319




320




321




323




324




325




327




328




329




330




331




333




334




335




336




337




339




340




341




342




343




344




347




348




350




351




352




354




357




358




359




361




366




367




368




369




370




371




372




373




374




375




376




378




379




380




381




383




384




385




386




387




388




389




390




392




393




394




395




396




397




399




400




401




402




403




404




405




407




410




411



412



413



414

22. A compound for use according to any preceding claim, which compound comprises:
- an isolated enantiomer, or
- a mixture of two or more enantiomers, or
- a mixture of two or more diastereomers, and/or epimers, or
- a racemic mixture, or
- a tautomer of the compound.

23. A compound for use according to any preceding claim which is selective for PARP1 over PARP2.

24. A pharmaceutical composition comprising a compound as defined in any preceding claim.

25. A pharmaceutical composition according to claim 24, further comprising a pharmaceutically acceptable additive and/or excipient, and/or wherein the compound is in the form of a pharmaceutically acceptable salt, hydrate, acid, ester, or other alternative form of the compound.

26. A compound for use according to any of claims 1 to 22, or a pharmaceutical composition according to claim 22 or claim 23, which is for use in treating a cancer.

27. A compound or pharmaceutical composition for use according to claim 26, wherein the cancer is a cancer selected from: a solid or liquid tumour including cancer of the eye, brain, spinal cord, kidney, mouth, lip, throat, oral cavity, nasal cavity, small intestine, colon,

parathyroid gland, gall bladder, head and neck, breast, bone, bile duct, cervix, heart, hypopharyngeal gland, lung, bronchus, liver, skin, ureter, urethra, testicles, vagina, anus, laryngeal gland, ovary, thyroid, oesophagus, nasopharyngeal gland, pituitary gland, salivary gland, prostate, pancreas, adrenal glands; an endometrial cancer, oral cancer, melanoma, neuroblastoma, gastric cancer, an angiomatosis, a hemangioblastoma, a pheochromocytoma, a pancreatic cyst, a renal cell carcinoma, Wilms' tumour, squamous cell carcinoma, sarcoma, osteosarcoma, Kaposi sarcoma, rhabdomyosarcoma, hepatocellular carcinoma, PTEN Hamartoma-Tumor Syndromes , leukaemias and lymphomas, nasopharyngeal and gastrointestinal cancers.

28. A compound or pharmaceutical composition for use according to claim 26 or claim 27, wherein the cancer is deficient in a DNA damage response repair pathway, such as Homologous Recombination dependent DNA Double Strand Break DNA repair activity.

29. A compound or pharmaceutical composition for use according to any of claims 26 to 28, wherein the cancer is deficient in BRCA1 and/or BRCA2 function.

30. A pharmaceutical composition for use according to claim 25 or claim 26, further comprising a further agent for treating cancer.

31. The pharmaceutical composition for use according to claim 30, wherein the further agent for treating cancer is selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, senolytic agents, hormones and hormone analogues, signal transduction pathway inhibitors, other DNA damage repair pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, antibody-drug conjugates, immunotherapeutic agents, hormone-deprivation therapy, proapoptotic agents and cell cycle signalling inhibitors.

32. The pharmaceutical composition for use according to claim 31, wherein the further agent is an immunotherapeutic agent selected from an anti-tumour vaccine, an oncolytic virus, an immune stimulatory antibody such as anti-CTLA4, anti-PD1, anti-PDL-1, anti-OX40, anti-41BB, anti-CD27, anti-CD40, anti-LAG3, anti-TIM3, and anti-GITR, a pattern recognition receptor agonist such as a STING, TLR-9 or RIG-I Helicase agonist, an IDO or TDO inhibitor, a novel adjuvant, a peptide, a cytokine, a chimeric antigen receptor T cell therapy, a small

molecule immune modulator, tumour microenvironment modulators, and anti-angiogenic agents.

33. A pharmaceutical kit for treating a cancer, which pharmaceutical kit comprises:

a) a compound as defined in any of claims 1 to 23; and

b) a further agent for treating cancer;

wherein the compound and the further agent are suitable for administration simultaneously, sequentially or separately.

34. The pharmaceutical kit according to claim 33, wherein the further agent for treating cancer is selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, senolytic agents, hormones and hormone analogues, signal transduction pathway inhibitors, other DNA damage repair pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, antibody-drug conjugates, hormone-deprivation therapy, immunotherapeutic agents, proapoptotic agents and cell cycle signalling inhibitors.

35. A compound, which is selected from any of the compounds defined in claim 21 or claim 22.

36. A method of synthesis of a PARP1 inhibitor compound as defined in any of claims 1 to 23, which method comprises conducting a reaction between i) a first reactant comprising ring E bearing a portion of substituent group L and ii) a second reactant comprising the remainder of substituent group L, so as to form the PARP1 inhibitor compound.

37. A method according to claim 36, wherein the reaction comprises alkylation, reductive amination or amide formation so as to form group L.